The conversion of preferred stock and doubling of authorized shares create a large overhang of potential dilution. Monitor for any subsequent equity offerings or ATM programs that could pressure the stock. The expanded equity plans suggest management anticipates needing to issue shares for compensation and potentially for capital raises.
Price Chart
Executive Summary
Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion of all outstanding Series B Convertible Preferred Stock into 20.4M common shares, doubling authorized common shares to 900M, and stockholder approval of increased equity incentive plans. These actions significantly expand the company's share count and authorized capital, signaling potential future dilution but also providing flexibility for financing and employee retention.
Key Facts
- All 408,434.7 shares of Series B Convertible Preferred Stock converted into 20,421,735 shares of common stock at a ratio of 50:1.
- Authorized common stock increased from 450M to 900M shares via Seventh Amended and Restated Certificate of Incorporation.
- 2026 Equity Incentive Plan approved, increasing share reserve from 75M to 90M shares.
- 2026 Non-Employee Directors Equity Incentive Plan approved, increasing share reserve from 4M to 6M shares.
- All proposals at the annual meeting passed with overwhelming stockholder support (over 97% of votes cast).
Financial Impact
Immediate issuance of 20.4M new common shares upon conversion of preferred stock; authorized share count doubled to 900M, enabling significant future dilution potential.
Risk Factors
- Significant dilution from 20.4M new shares hitting the market upon conversion.
- Doubling of authorized shares signals potential for further equity raises, which could be dilutive.
- Increased equity incentive plan capacity may lead to ongoing dilution from employee stock awards.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062822-26-000065 |
| Document: a2026equityincentiveplan.htm | 0001062822-26-000065 |
| Document: seventhamendedandrestate.htm | 0001062822-26-000065 |
| Document: a2026non-employeedirecto.htm | 0001062822-26-000065 |
| Document: 0001062822-26-000065-index-headers.html | 0001062822-26-000065 |
| Document: 0001062822-26-000065-index.html | 0001062822-26-000065 |
| Document: 0001062822-26-000065.txt | 0001062822-26-000065 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Aug 6, 2026 8w ago | Press Release | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Jun 12, 2026 16w ago | Institutional Cluster | $1.92 $2.22 | ▼ −15.63% | ▼ −13.85% | $1.82 (+5.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.89 $2.25 | ▲ +19.05% | ▲ +17.16% | $1.82 (−3.70%) |
May 6, 2026 21w ago | 8-K | $1.68 $1.85 | ▲ +10.12% | ▲ +6.98% | $1.82 (+8.33%) |
Apr 30, 2026 22w ago | 8-K | $1.63 $2.07 | ▼ −26.99% | ▼ −21.71% | $1.82 (−11.66%) |
Apr 30, 2026 22w ago | Press Release | $1.61 $2.21 | ▲ +37.27% | ▲ +32.30% | $1.82 (+13.04%) |
Mar 24, 2026 27w ago | Press Release | $1.72 $1.82 | ▲ +5.81% | ▼ −3.09% | $1.82 (+5.81%) |
Mar 23, 2026 27w ago | Press Release | $1.64 $1.83 | ▲ +11.59% | ▲ +4.17% | $1.82 (+10.98%) |
Mar 16, 2026 28w ago | DEFA14A | $1.62 $1.86 | ▲ +14.81% | ▲ +10.51% | $1.82 (+12.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access